Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS

• by Yue Xi, Ying Liang, Zhi Chen, Lei Lei, Lan Mi, Xiaoyu Tian, Liuyu Sun, Qiang Sun, Nan Zhou

• April 23, 2026

Child Opportunity Index and Prevalence of Obesity and Hypertension in Adolescents with Congenital Heart Disease

• by Andrew H. Tran, Patrick R. Dusza, Robin Alexander, Chance Alvarado, Kan N. Hor

• May 2, 2026

Case Report: Early diagnosis of X-linked Alport syndrome in a pediatric patient and literature review

• by Yushan Gong, Hui Guo, Zhouhang Yang

• May 21, 2026

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.

• by Taylor P. Robichaux, Kathryn E. Dane, P. Christopher Parish, Justin R. Arnall, Donald C. Moore

• January 9, 2026

• 15 min